B+
Bull case
30%
Probability
Target price
$6.25
+35.3% vs current
CLOV
Clover Health InvestmentsANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.80
+3.9% vs current
B-
Bear case
25%
Probability
Target price
$3.10
-32.9% vs current
AI sentiment snapshot
Latest data as of 2026-07-09
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+50.0
Score
AI commentary
Primary-source tone is positive because the May 6, 2026 earnings release showed profitability and full-year confidence, while the June 18, 2026 8-K added a favorable CMS star-rating recalculation for payment year 2027 [#SEC-8K-2026-05-06] [#8-K-2026-06-18]. Still, news volume in the packet is light, the non-primary coverage is mostly summary-style or retail-oriented, and no robust analyst revision set is available, so this remains a cautious positive-monitoring view rather than a high-conviction call.
RankAlpha Sentiment Codex - 2026-07-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-05catalystNext earnings need to confirm medical-cost and SG&A discipline on the larger membership baseHigh impact
Management said early medical cost trend indicators across both new and returning cohorts were encouraging, but the next report still has to show that benefit expense ratio, claims development, and SG&A leverage remain controlled as rapid Medicare Advantage growth seasons [#SEC-8K-2026-05-06].
2026-12-31catalyst2026 first full-year profitability remains the main rerating hookHigh impact
The Q1 earnings release showed $749.2 million of revenue, $27.3 million of GAAP net income, $40.3 million of adjusted EBITDA, and management said it expects to meet or exceed full-year 2026 outlook including first full-year GAAP net income profitability [#SEC-8K-2026-05-06].
2027-01-01event2027 Star-rating recalculation improved payment-year economicsHigh impact
Clover disclosed that CMS recalculated its PPO contract H5141 from 3.5 to 4.5 Stars for payment year 2027 and that HPMS also showed its HMO contract H8010 increasing from 4.0 to 4.5 Stars, which can improve bonus payments and marketing competitiveness if the revised ratings hold [#8-K-2026-06-18].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-09 • Updated nightlySource: Internal modelMethodology